Last reviewed · How we verify

LM-302 Injection — Competitive Intelligence Brief

LM-302 Injection (LM-302 Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

phase 3 Unknown Oncology Small molecule Live · refreshed every 30 min

Target snapshot

LM-302 Injection (LM-302 Injection) — LaNova Medicines Zhejiang Co., Ltd.. LM-302 Injection is a monoclonal antibody targeting a specific molecular target.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
LM-302 Injection TARGET LM-302 Injection LaNova Medicines Zhejiang Co., Ltd. phase 3 Unknown
SINECATECHINS SINECATECHINS marketed Polyphenols Unknown 2006-01-01
PODOFILOX PODOFILOX marketed Topical antiviral Unknown 1990-01-01
POLIDEXIDE SULFATE POLIDEXIDE SULFATE marketed Unknown Unknown 1974-01-01
SUTILAINS SUTILAINS marketed Unknown Unknown 1969-01-01
Pf-08032562 pf-08032562 Pfizer Inc. marketed unknown unknown
Latanoprost plus adjunctive glaucoma medication Latanoprost plus adjunctive glaucoma medication Sight Sciences, Inc. marketed Prostaglandin analog with adjunctive glaucoma agent FP prostaglandin receptor (latanoprost component); adjunctive target unknown

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LM-302 Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/lm-302-injection. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: